Increased Expression of BRCA1 mRNA Predicts Favorable Response to Anthracycline-Containing Chemotherapy in Breast Cancers

[1]  M. J. van de Vijver,et al.  Determining MDR1/P‐glycoprotein expression in breast cancer , 2001, International journal of cancer.

[2]  M. Piccart,et al.  Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Miyoshi,et al.  Quantitative Analysis of BRCA1 and BRCA2 mRNA Expression in Sporadic Breast Carcinomas and Its Relationship with Clinicopathological Characteristics , 2001, Japanese journal of cancer research : Gann.

[4]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[5]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[6]  K. Holli,et al.  c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. , 2001, European journal of cancer.

[7]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. King,et al.  Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.

[9]  K. Goa,et al.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. , 1999, Drugs & aging.

[10]  I. Bièche,et al.  Overexpression of BRCA2 gene in sporadic breast tumours , 1999, Oncogene.

[11]  L. Chow,et al.  Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer , 1999, Oncogene.

[12]  I. Ellis,et al.  BRCA1 expression levels predict distant metastasis of sporadic breast cancers , 1999, International journal of cancer.

[13]  Y. Miki,et al.  Clinicopathologic analysis of BRCA1‐ or BRCA2‐associated hereditary breast carcinoma in Japanese women , 1999, Cancer.

[14]  A. Goldhirsch,et al.  Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.

[15]  R. Fleming.  An Overview of Cyclophosphamide and Ifosfamide Pharmacology , 1997, Pharmacotherapy.

[16]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[17]  H. Caffier,et al.  A somatic truncating mutation in BRCA2 in a sporadic breast tumor. , 1996, American journal of human genetics.

[18]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[19]  Yusuke Nakamura,et al.  Mutation analysis in the BRCA2 gene in primary breast cancers , 1996, Nature Genetics.

[20]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[21]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[22]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[23]  K. Kohn,et al.  Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. , 1990, Biochemistry.

[24]  J. Roh,et al.  P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer , 2004, Breast Cancer Research and Treatment.

[25]  F. Pannuti,et al.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study , 2004, Cancer Chemotherapy and Pharmacology.

[26]  M. Daidone,et al.  Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. , 1994, European journal of cancer.